Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01257828 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect)
A Phase 3 study, sponsored by AOSpine North America Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 270
- Enrollment target
NCT01257828 is a Phase 3 study that has completed, run by AOSpine North America Research Network. The registered enrollment target is 270 participants.
The verdict
NCT01257828, a Phase 3 study, has completed, sponsored by AOSpine North America Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 270 participants
- Enrollment target
Study Summary
CSM (Cervical spondylotic myelopathy) is the most common cause of spinal cord injury worldwide. While there is evidence from the recently completed SpineNet prospective study that surgical decompression is an effective treatment for CSM, it is clear that many patients have remaining neurological impairment. While surgery is relatively safe, approximately 3% of patients maintain a neurological problem. Given this background and data from preclinical models of non-traumatic and traumatic spinal cord injury, there is strong evidence to consider the potential benefit of adding a neuroprotective drug which aids in the treatment of patients with CSM whom are undergoing surgical decompression. Riluzole is FDA-approved for the treatment of amyotrophic lateral sclerosis, which has some similar clinical features to CSM. Riluzole is currently under investigation for traumatic spinal cord injury. Given this background, there is a strong basis to consider studying the potential neurological benefits of Riluzole as a treatment to surgical decompression in patients with CSM.
Interventions
- DRUG Placebo medication
- DRUG riluzole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2012-03 |
| Est. Completion | 2018-06-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01257828
The ClinicalTrials.gov registry entry for NCT01257828 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AOSpine North America Research Network, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo medication is the first listed.
NCT01257828 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01257828 about?
NCT01257828 is a clinical study titled "Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect)". CSM (Cervical spondylotic myelopathy) is the most common cause of spinal cord injury worldwide. While there is evidence from the recently completed SpineNet prospective study that surgical decompression is an effective treatment for CSM, it is clear that many patients have remaining neurological imp...
What is the current status of trial NCT01257828?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 270 participants. The study started on 2012-03. Estimated completion is 2018-06-01.
What interventions are being tested in trial NCT01257828?
The interventions under investigation include: Placebo medication (DRUG), riluzole (DRUG).
Who is sponsoring clinical trial NCT01257828?
This trial is sponsored by AOSpine North America Research Network, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.